Sarepta Therapeutics (SRPT) Research & Development (2010 - 2026)

Sarepta Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $154.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 80.09% year-over-year to $154.0 million in Q1 2026; TTM through Mar 2026 was $902.6 million, a 34.48% decrease from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 89.19% from the prior year.
• Research & Development eased to $154.0 million in Q1 2026 per SRPT's latest filing, from $325.3 million in the prior quarter.
• Across five years, Research & Development topped out at $773.4 million in Q1 2025 and bottomed at $154.0 million in Q1 2026.
• The 5-year median for Research & Development is $213.8 million (2022), against an average of $249.1 million.
• Across the five-year window, Research & Development jumped 285.96% in 2025 and plunged 80.09% in 2026, its largest moves.
• Year by year, Research & Development stood at $213.8 million in 2022, then decreased by 8.55% to $195.5 million in 2023, then rose by 2.27% to $200.0 million in 2024, then jumped by 62.71% to $325.3 million in 2025, then plunged by 52.68% to $154.0 million in 2026.
• Per Business Quant, the three latest SRPT Research & Development figures stand at $154.0 million (Q1 2026), $325.3 million (Q4 2025), and $218.9 million (Q3 2025).